Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies
S Sloot, YA Chen, X Zhao, JL Weber, JJ Benedict… - Cancer, 2018 - Wiley Online Library
BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …
failure in patients with melanoma and has been associated with a poor prognosis. Recent …
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies
Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …
Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort
The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …
therapy trials have generated substantial promise for revolutionizing the management of …
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
E Vosoughi, JM Lee, JR Miller, M Nosrati, DR Minor… - BMC cancer, 2018 - Springer
Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …
Current treatment of melanoma brain metastasis
A Rishi, HHM Yu - Current Treatment Options in Oncology, 2020 - Springer
Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …
Changes in outcomes and factors associated with survival in melanoma patients with brain metastases
M Hasanov, DR Milton, AB Davies, E Sirmans… - Neuro …, 2023 - academic.oup.com
Background Treatment options for patients with melanoma brain metastasis (MBM) have
changed significantly in the last decade. Few studies have evaluated changes in outcomes …
changed significantly in the last decade. Few studies have evaluated changes in outcomes …
Melanoma brain metastases–Interdisciplinary management recommendations 2020
R Gutzmer, D Vordermark, JC Hassel, D Krex… - Cancer Treatment …, 2020 - Elsevier
Melanoma brain metastases (MBM) are common and associated with a particularly poor
prognosis; they directly cause death in 60–70% of melanoma patients. In the past, systemic …
prognosis; they directly cause death in 60–70% of melanoma patients. In the past, systemic …
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a …
F Spagnolo, V Picasso, M Lambertini, V Ottaviano… - Cancer treatment …, 2016 - Elsevier
Background The incidence of brain metastases (BM) in melanoma patients is common and
associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint …
associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint …
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric …
P Tétu, C Allayous, B Oriano, S Dalle, L Mortier… - European Journal of …, 2019 - Elsevier
Abstract Background Melanoma brain metastases (MBMs) are historically associated with
poor prognosis. Radiation therapy is conventionally associated with a high local control rate …
poor prognosis. Radiation therapy is conventionally associated with a high local control rate …
[HTML][HTML] Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
相关搜索
- brain metastases melanoma patients
- checkpoint inhibitors targeted therapies
- changes in outcomes melanoma patients
- map kinase survival of patients
- brain metastases changes in outcomes
- brain metastases map kinase
- clinical outcomes targeted therapies
- brain metastases survival of patients
- metastatic melanoma survival of patients
- brain metastases metastatic melanoma